Page 333 - எங்களுக்கு தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Latest: Tunisia extends curfew past New Year s holiday

The Latest: Coronavirus cases keep rising in South Korea Associated Press Updated: Tags: Copyright 2020 The Associated Press. All rights reserved Volunteers wearing face masks wave after they load boxes onto a delivery truck during an event to send Christmas gifts for the underprivileged in Seoul, South Korea, Tuesday, Dec. 22, 2020. The Korea Youth Foundation sent Christmas gifts using a courier to help prevent against the coronavirus as the social distancing measures. (AP Photo/Lee Jin-man) SEOUL, South Korea South Korea has added 1,092 new coronavirus cases in a resurgence that is erasing hard-won epidemiological gains and eroding public confidence in the government’s ability to handle the outbreak.

United statesUnited arab emiratesFrance generalUnited kingdomSan joaquin valleySouth carolinaKentucky houseMinistry of healthImperial countySouth africaPasteur instituteBrian kempFaouzi madhiBritainy beshearDonald trumpHachemi louzir

Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties

Published: Dec 21, 2020 CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that it will move forward with a singular focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates, and has entered into a definitive agreement to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company. Agios will receive a cash consideration of up to $2.0 billion, including $1.8 billion in upfront cash and $200 million in a potential future milestone payment for vorasidenib, as well as 5% royalties on U.S. net sales of TIBSOVO

United statesUnited kingdomRosen katzJessica rennekampOlivier laureauBristol myers squibbDavidk leeHolly manningJackie fouseDevelopment agreementUs national institutes of healthServier groupExchange commissionCorporate communicationsServier pharmaceuticalsGoldman sachs co

NIH pauses enrollment of critically ill patients in trials testing blood thinners against COVID-19

NIH pauses enrollment of critically ill patients in trials testing blood thinners against COVID-19
katcountry989.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from katcountry989.com Daily Mail and Mail on Sunday newspapers.

Manojna maddipatlaMaju samuelUs national institutes of healthமஜு சாமுவேல்எங்களுக்கு தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம்

US Health Agency to Examine Causes of Severe Allergic Reactions to Pfizer s COVID-19 Vaccine

US Health Agency to Examine Causes of Severe Allergic Reactions to Pfizer’s COVID-19 Vaccine © REUTERS / Frank Augstein Subscribe Sputnik International https://sputniknews.com/society/202012221081534605-us-health-agency-to-examine-causes-of-severe-allergic-reactions-to-pfizers-covid-19-vaccine/ A new study on allergic reactions to the COVID-19 vaccine comes as hundreds of thousands of Americans have been inoculated against the respiratory disease and as officials begin to ship out millions of doses of the Moderna COVID-19 vaccine. The US National Institutes of Health is set to launch a new study to allow an in-depth examination into the rare but severe allergic reactions that, so far, only a handful of individuals have experienced since the deployment of the Pfizer-BioNTech COVID-19 vaccine.

United statesDaniel rotrosenJoe bidenDivision of allergyWashington postNational institute of allergyUs centers for diseaseUs national institutes of healthNational instituteInfectious diseasesDisease controlஒன்றுபட்டது மாநிலங்களில்ஓஹோ பிடென்பிரிவு ஆஃப் ஒவ்வாமைவாஷிங்டன் போஸ்ட்தேசிய நிறுவனம் ஆஃப் ஒவ்வாமை

Australia must do more to prepare for a SolarWinds-style supply-chain attack

The Australian government’s 2020 cyber security strategy is overwhelmingly focused on increasing the cybersecurity efforts of the defence organisation and law enforcement agencies. The mounting crisis in the United States from the hacking of software company SolarWinds indicates that this is not enough. On 12 December, cybersecurity firm FireEye announced it had detected an alleged Russian cyberattack that had compromised the monitoring and management software on SolarWinds’ commonly used Orion network to get access to victim organisations potentially 18,000 of them. The US National Institutes of Health and the departments of Treasury, Commerce, Homeland Security and State are reported to be among the victims.

United statesNew zealandUnited kingdomChinese ministry of state securityUs national security agencyUs department of justiceOffice of the australian informationAustralian prudential regulation authorityInvestments commissionUs state departmentUs national institutes of healthConsumer commissionHomeland securityCloud hopperChinese ministryState security